![Peter Radovich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Radovich
Präsident bei
MIRUM PHARMACEUTICALS, INC.
Vermögen: 5 Mio $ am 30.09.2026
Profil
Mr. Peter Radovich is an Independent Director at MBX Biosciences, Inc. and a President & Chief Operating Officer at Mirum Pharmaceuticals, Inc. He is on the Board of Directors at MBX Biosciences, Inc. Mr. Radovich was previously employed as an Independent Director by Rain Oncology, Inc., a Senior Vice President-Operations by Global Blood Therapeutics, Inc., a Vice President-Global Product Kyprolis by Onyx Pharmaceuticals, Inc., a Principal by Chiron Corp., and a Senior Director & VP-Program Leadership by Onyx Pharmaceuticals, Inc. He received his undergraduate degree from Texas Christian University and an MBA from the University of Washington.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.06.2026 | 57.260 ( 0,09 % ) | 5 Mio $ | 30.09.2026 |
Aktive Positionen von Peter Radovich
| Unternehmen | Position | Beginn |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Präsident | 16.01.2024 |
| MBX BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 20.10.2026 |
Ehemalige bekannte Positionen von Peter Radovich
| Unternehmen | Position | Ende |
|---|---|---|
| RAIN ONCOLOGY INC. | Direktor/Vorstandsmitglied | 25.01.2024 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Geschäftsführer | 01.04.2020 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01.01.2014 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Direktor/Vorstandsmitglied | 01.09.2006 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Corporate Officer/Principal | 01.01.2006 |
Ausbildung von Peter Radovich
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
67
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Texas Christian University
 Texas Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Rain Oncology, Inc.
 Rain Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage precision oncology company that develops therapeutics for cancer patients | Health Technology |
Mirum Pharmaceuticals, Inc.
 Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
MBX Biosciences, Inc.
 MBX Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on discovery and development of novel precision peptide therapies for endocrine & metabolic disorders | Health Technology |
